Source: WSJ

SuppreMol: Baxter Buys Autoimmune Specialist SuppreMol

Baxter International agreed to buy German biopharmaceutical company SuppreMol for about €200 million, in a move to improve its portfolio of autoimmune treatments.

Read full article »
SuppreMol's Competitors | SuppreMol's News | SuppreMol's Financials
Stay up-to-date with the latest news on SuppreMol
Est. Annual Revenue
$5.0-25M
Est. Employees
25-100
Klaus Schollmeie's photo - CEO of SuppreMol

CEO

Klaus Schollmeie

CEO Approval Rating

68/100

Read more
Stay up-to-date with the latest news on SuppreMol